Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30613704 | 1.00 | KMO (0.43) | KMOLMNASMN1; SMN2TYK2ASPH | |
| SCHEMBL28281719 | 0.86 | TYK2 (0.39) | KMOLMNASMN1; SMN2TYK2S1PR3 | |
| SCHEMBL27592637 | 0.84 | TYK2 (0.38) | KMOTYK2S1PR3HTTHSD17B10 | |
| SCHEMBL28764418 | 0.82 | GLRA3 (0.43) | KMOLMNASMN1; SMN2ASPHKDM4E | |
| SCHEMBL8288534 | 0.81 | SMN1; SMN2 (0.41) | KMOLMNASMN1; SMN2TYK2ASPH | |
| SCHEMBL6381481 | 0.80 | ATR (0.44) | TYK2KDM4ES1PR3HSD17B10 | |
| SCHEMBL1699267 | 0.80 | NAPRT (0.43) | KMOTYK2ASPHKDM4EKDM8 | |
| SCHEMBL15880100 | 0.79 | HSD17B10 (0.43) | KMOASPHKDM4EKDM8HTT | |
| SCHEMBL14907699 | 0.79 | KMO (0.41) | KMOSMN1; SMN2TYK2ASPHKDM4E | |
| SCHEMBL148901 | 0.79 | AAK1 (0.44) | KMOASPHKDM4EKDM8HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106771303-A | One kind is for analyzing conveying device and its method of work in heavy metal-polluted soil sample injector | 徐州工程学院 | 2017-05-31 | — | — | CN | claimed |
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2025-08-21 | — | — | US | disclosed |
| US-20250066368-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2025-02-27 | — | — | US | disclosed |
| CN-118894856-A | Pyrazole-containing polycyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-118894855-A | Pyrazole-containing polycyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| EP-4455129-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2024-10-30 | — | — | EP | disclosed |
| CN-118451067-A | DNA polymerase theta inhibitor and application thereof | 上海湃隆生物科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-114222746-B | Pyrazole-containing polycyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| WO-2023193054-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023125918-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2014113303-A1 | 4-FLUOROPIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014113303-A1 | 4-FLUOROPIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| CN-103694168-A | Method for preparing 6-chlorine-4-trifluoromethyl-3-cyanopyridine | GUIZHOU WYLTON JINGLIN ELECTRONIC MATERIALS CO LTD | 2014-04-02 | — | — | CN | disclosed |
| EP-1893566-B1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME (GB) | 2013-02-13 | — | — | EP | disclosed |
| US-7851638-B2 | Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia | MERCK SHARP & DOHME LIMITED (GB) | 2010-12-14 | — | — | US | disclosed |
| US-20100029726-A1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-7626056-B2 | 2,4-Dichloro-N-(4-cyclopropylmethanesulfonyl-1-cyclopropylmethylcyclohexyl-methyl) benzamide; glutamatergic neurotransmission dysfunction and diseases; dementia; antidepressants; learning enhancement; cognition activators; attention deficit disorders; autism; eating disorders; anxiolytic agents | MERCK SHARP & DOHME LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| EP-1893566-A1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME LTD. (GB) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006131711-A1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-14 | — | — | WO | disclosed |
| US-20060276655-A1 | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276655-A1 | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia | GLRA1, GNMT, MGAT1 | KMO 489/4885LMNA 4558/4885SMN1; SMN2 4074/4885 |
| US-20250066368-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | POLQ, POLB, POLM | KMO 3441/4885LMNA 718/4885SMN1; SMN2 2924/4885 |
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | LCK, BTK, SYK | KMO 281/4885LMNA 4746/4885SMN1; SMN2 2385/4885 |
| US-20100029726-A1 | CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA | GLRA1, GNMT, MGAT1 | KMO 489/4885LMNA 4558/4885SMN1; SMN2 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.